La Jolla Pharmaceutical Tries Higher-Dose Riquent Against Lupus
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA could be submitted this year, company says.
You may also be interested in...
BioMarin Saves Day For La Jolla's Riquent, But All Hangs On Pivotal Trial
With new financing in hand courtesy of BioMarin, La Jolla now hopes to complete its pivotal ASPEN trial for Riquent (abetimus) in lupus nephritis and launch in the U.S. in late 2010
BioMarin Saves Day For La Jolla's Riquent, But All Hangs On Pivotal Trial
With new financing in hand courtesy of BioMarin, La Jolla now hopes to complete its pivotal ASPEN trial for Riquent (abetimus) in lupus nephritis and launch in the U.S. in late 2010
Rituxan For Lupus Misses Primary, Secondary Endpoints
Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.